{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:50:27Z","timestamp":1752231027248},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11886-021-01605-0","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T20:15:41Z","timestamp":1635624941000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Stroke Prevention in Patients with Patent Foramen Ovale"],"prefix":"10.1007","volume":"23","author":[{"given":"Alison","family":"Thaler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Kvernland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo J.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Mac Grory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Yaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"issue":"1","key":"1605_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0025-6196(12)60336-X","volume":"59","author":"PT Hagen","year":"1984","unstructured":"Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin Proc. 1984;59(1):17\u201320.","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"1605_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jacc.2018.03.549","volume":"72","author":"MK Mojadidi","year":"2018","unstructured":"Mojadidi MK, et al. Cryptogenic stroke and patent foramen ovale: ready for prime time? J Am Coll Cardiol. 2018;72(10):1183\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1605_CR3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1474-4422(13)70310-7","volume":"13","author":"RG Hart","year":"2014","unstructured":"Hart RG, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):429\u201338.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1605_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1212\/WNL.0b013e3182a08d59","volume":"81","author":"DM Kent","year":"2013","unstructured":"Kent DM, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013;81(7):619\u201325.","journal-title":"Neurology"},{"issue":"7","key":"1605_CR5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1001\/jamaneurol.2020.0458","volume":"77","author":"AY Elgendy","year":"2020","unstructured":"Elgendy AY, et al. Proposal for updated nomenclature and classification of potential causative mechanism in patent foramen ovale-associated stroke. JAMA Neurol. 2020;77(7):878\u201386.","journal-title":"JAMA Neurol"},{"issue":"20","key":"1605_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1212\/WNL.0000000000009443","volume":"94","author":"SR Messe","year":"2020","unstructured":"Messe SR, et al. Practice advisory update summary: patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology. 2020;94(20):876\u201385.","journal-title":"Neurology"},{"issue":"11","key":"1605_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","volume":"377","author":"JL Mas","year":"2017","unstructured":"Mas JL, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med. 2017;377(11):1011\u201321.","journal-title":"N Engl J Med"},{"key":"1605_CR8","unstructured":"\u2022 Diener HC, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906\u201317. In this study, anticoagulation was not superior to aspirin in reducing recurrent stroke risk in patients with cryptogenic stroke and evidence of PFO."},{"issue":"12","key":"1605_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1474-4422(18)30319-3","volume":"17","author":"SE Kasner","year":"2018","unstructured":"Kasner SE, et al. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol. 2018;17(12):1053\u201360.","journal-title":"Lancet Neurol"},{"issue":"35","key":"1605_CR10","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1093\/eurheartj\/ehv252","volume":"36","author":"DM Kent","year":"2015","unstructured":"Kent DM, et al. Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis. Eur Heart J. 2015;36(35):2381\u20139.","journal-title":"Eur Heart J"},{"issue":"1","key":"1605_CR11","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000005736","volume":"91","author":"H Saber","year":"2018","unstructured":"Saber H, et al. Network meta-analysis of patent foramen ovale management strategies in cryptogenic stroke. Neurology. 2018;91(1):e1\u20137.","journal-title":"Neurology"},{"issue":"38","key":"1605_CR12","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1093\/eurheartj\/ehy649","volume":"40","author":"C Pristipino","year":"2019","unstructured":"Pristipino C, et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. Eur Heart J. 2019;40(38):3182\u201395.","journal-title":"Eur Heart J"},{"issue":"11","key":"1605_CR13","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1009639","volume":"366","author":"AJ Furlan","year":"2012","unstructured":"Furlan AJ, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366(11):991\u20139.","journal-title":"N Engl J Med"},{"issue":"12","key":"1605_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMoa1301440","volume":"368","author":"JD Carroll","year":"2013","unstructured":"Carroll JD, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368(12):1092\u2013100.","journal-title":"N Engl J Med"},{"issue":"12","key":"1605_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa1211716","volume":"368","author":"B Meier","year":"2013","unstructured":"Meier B, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med. 2013;368(12):1083\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"1605_CR16","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1707404","volume":"377","author":"L Sondergaard","year":"2017","unstructured":"Sondergaard L, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med. 2017;377(11):1033\u201342.","journal-title":"N Engl J Med"},{"issue":"11","key":"1605_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1610057","volume":"377","author":"JL Saver","year":"2017","unstructured":"Saver JL, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med. 2017;377(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"20","key":"1605_CR18","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","volume":"71","author":"PH Lee","year":"2018","unstructured":"Lee PH, et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018;71(20):2335\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1605_CR19","doi-asserted-by":"publisher","first-page":"e023761","DOI":"10.1136\/bmjopen-2018-023761","volume":"8","author":"H Mir","year":"2018","unstructured":"Mir H, et al. Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open. 2018;8(7):e023761.","journal-title":"BMJ Open"},{"issue":"6","key":"1605_CR20","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/ccd.22172","volume":"74","author":"S Staubach","year":"2009","unstructured":"Staubach S, et al. New onset atrial fibrillation after patent foramen ovale closure. Catheter Cardiovasc Interv. 2009;74(6):889\u201395.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"1605_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10840-020-00925-5","volume":"60","author":"L Oliva","year":"2021","unstructured":"Oliva L, et al. New-onset atrial fibrillation following percutaneous closure of patent foramen ovale: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2021;60(2):165\u201374.","journal-title":"J Interv Card Electrophysiol"},{"key":"1605_CR22","unstructured":"\u2022 Chen JZ, Thijs VN. Atrial fibrillation following patent foramen ovale closure: systematic review and meta-analysis of observational studies and clinical trials. Stroke. 2021:STROKEAHA120030293. This study confirms the increased odds of atrial fibrillation in patients undergoing PFO closure (OR 5.3, 95% CI 2.50\u201311.41, p<0.001)."},{"issue":"18","key":"1605_CR23","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1093\/eurheartj\/ehy121","volume":"39","author":"Y Ahmad","year":"2018","unstructured":"Ahmad Y, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018;39(18):1638\u201349.","journal-title":"Eur Heart J"},{"issue":"12","key":"1605_CR24","doi-asserted-by":"publisher","first-page":"e008356","DOI":"10.1161\/JAHA.117.008356","volume":"7","author":"G Turc","year":"2018","unstructured":"Turc G, et al. Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE study. J Am Heart Assoc. 2018;7(12):e008356.","journal-title":"J Am Heart Assoc"},{"key":"1605_CR25","doi-asserted-by":"crossref","unstructured":"\u2022 Garg A, et al. Recurrent stroke reduction with patent foramen ovale closure versus medical therapy based on patent foramen ovale characteristics: a meta-analysis of randomized controlled trials. Cardiology. 2019;144;(1\u20132):40\u201349. This is meta-analysis of randomized trials testing PFO closure showing that among patients with cryptogenic stroke, PFO closure is associated with a significantly reduced risk of recurrent stroke compared to MT. Additionally, the benefit of PFO closure might be dependent on certain PFO characteristics.","DOI":"10.1159\/000500501"},{"issue":"5","key":"1605_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1161\/01.STR.0000068408.82115.D2","volume":"34","author":"SE Vermeer","year":"2003","unstructured":"Vermeer SE, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34(5):1126\u20139.","journal-title":"Stroke"},{"issue":"4","key":"1605_CR27","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1161\/STROKEAHA.109.570044","volume":"41","author":"S Debette","year":"2010","unstructured":"Debette S, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke. 2010;41(4):600\u20136.","journal-title":"Stroke"},{"issue":"12","key":"1605_CR28","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1161\/STROKEAHA.109.559898","volume":"40","author":"MR Clergeau","year":"2009","unstructured":"Clergeau MR, et al. Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study. Stroke. 2009;40(12):3758\u201362.","journal-title":"Stroke"},{"issue":"2","key":"1605_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1468-1331.2012.03864.x","volume":"20","author":"SJ Kim","year":"2013","unstructured":"Kim SJ, et al. Paradoxical embolism as a cause of silent brain infarctions in healthy subjects: the ICONS study (Identification of the Cause of Silent Cerebral Infarction in Healthy Subjects). Eur J Neurol. 2013;20(2):353\u201360.","journal-title":"Eur J Neurol"},{"issue":"10","key":"1605_CR30","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00380-019-01379-0","volume":"34","author":"H Takafuji","year":"2019","unstructured":"Takafuji H, et al. Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly. Heart Vessels. 2019;34(10):1657\u201362.","journal-title":"Heart Vessels"},{"issue":"3","key":"1605_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.recesp.2019.07.009","volume":"73","author":"J Wintzer-Wehekind","year":"2020","unstructured":"Wintzer-Wehekind J, et al. Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism. Rev Esp Cardiol (Engl Ed). 2020;73(3):219\u201324.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"12","key":"1605_CR32","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1161\/STR.0000000000000211","volume":"50","author":"WJ Powers","year":"2019","unstructured":"Powers WJ, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association\/American Stroke Association. Stroke. 2019;50(12):e344\u2013418.","journal-title":"Stroke"},{"issue":"4","key":"1605_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2396987319863606","volume":"4","author":"N Ahmed","year":"2019","unstructured":"Ahmed N, et al. Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11\u201313 November 2018. Eur Stroke J. 2019;4(4):307\u201317.","journal-title":"Eur Stroke J"},{"issue":"17","key":"1605_CR34","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.4244\/EIJ-D-18-00767","volume":"14","author":"AY Elgendy","year":"2019","unstructured":"Elgendy AY, et al. New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention. 2019;14(17):1788\u201390.","journal-title":"EuroIntervention"},{"issue":"11","key":"1605_CR35","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1161\/STROKEAHA.117.018501","volume":"48","author":"AE Merkler","year":"2017","unstructured":"Merkler AE, et al. Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. Stroke. 2017;48(11):3073\u20137.","journal-title":"Stroke"},{"issue":"5","key":"1605_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/ccd.28111","volume":"93","author":"E Horlick","year":"2019","unstructured":"Horlick E, et al. SCAI expert consensus statement on operator and institutional requirements for PFO closure for secondary prevention of paradoxical embolic stroke: the American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Catheter Cardiovasc Interv. 2019;93(5):859\u201374.","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01605-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-021-01605-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-021-01605-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T17:22:42Z","timestamp":1637860962000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-021-01605-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s11886-021-01605-0","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"31 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"183"}}